The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a ...

The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

Recognizing the urgent need for treatment options and guided by patient insights, Pfizer scientists have discovered a way to ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...